10-Q · July 29, 2026
uniQure grew Q2 license revenue 11.0% year over year to $5.841 million and raised gross margin to 94.0%, but its net loss more than doubled to $81.059 million, or $1.22 per share. Liquidity improved substantially after…
Earnings analysis · 10-Q
QURE earnings analysis
Filed November 4, 2026 · Our reading of the company's report
The latest report
Q3 revenue of $5.2 million missed the $5.7732 million consensus estimate, while diluted EPS of $(0.88) also missed the $(0.82) estimate; revenue declined from $6 million in Q2 2026 but increased from $4 million a year…
Read full summary
Q3 revenue of $5.2 million missed the $5.7732 million consensus estimate, while diluted EPS of $(0.88) also missed the $(0.82) estimate; revenue declined from $6 million in Q2 2026 but increased from $4 million a year earlier. The company reported $768.4 million of cash, cash equivalents and investment securities, expected to fund operations into 2030. Regulatory progress for ifezuntirgene inilparvovec was favorable, with FDA acceptance and a May 1, 2027 PDUFA date, but the 48-month cUHDRS endpoint was not statistically significant in 12 high-dose patients, leaving substantial approval and confirmatory-study risk.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.88
What stood out
-
Revenue missed consensus
Q3 revenue was $5.2 million, down from $6 million in Q2 2026 but up from $4 million in Q3 2025. Revenue was below the $5.7732 million consensus estimate.
-
EPS improved year over year
Diluted EPS was $(0.88), an improvement from $(1.22) in Q2 2026 and $(1.38) in Q3 2025, but below the $(0.82) consensus estimate.
-
Cash runway extends into 2030
Cash, cash equivalents and investment securities totaled $768.4 million and management expects this balance to fund operations into 2030, supporting liquidity for development activities.
-
Regulatory milestones advanced
The FDA accepted the BLA for ifezuntirgene inilparvovec in October 2026 and assigned a PDUFA target action date of May 1, 2027; the MHRA subsequently validated the MAA submitted in Q3 2026.
What to watch
-
Approval remains uncertain
The FDA stated it is tentatively planning an Advisory Committee meeting, and the BLA has a May 1, 2027 PDUFA target date; neither date assures approval or timely action.
-
Long-term efficacy data is a concern
In the 12 high-dose patients with 48 months of follow-up, the prespecified cUHDRS endpoint did not reach statistical significance. The 36-month analysis covered 15 high-dose patients and used nominal p-values not adjusted for multiplicity.
-
Securities litigation remains outstanding
A securities class action was filed on February 10, 2026, and an amended complaint was filed on July 15, 2026; the defendants' motion to dismiss was due November 4, 2026. No liability was recorded because management concluded the loss was not probable and reasonably estimable.
Management's outlook
No quantitative revenue or EPS guidance was provided in the 10-Q. Management stated that $768.4 million of cash, cash equivalents and investment securities is expected to fund operations into 2030.
Earlier filings 4
10-Q · May 5, 2026
uniQure reported Q1 2026 revenues of $3.56 million, missing the consensus estimate of $4.98 million, while EPS was -$0.85, also below the estimated -$0.78. Management highlighted ongoing high R&D expenses primarily due…
10-K · March 2, 2026
uniQure positions itself as a leader in CNS gene therapies with a concentrated pipeline led by AMT-130 for Huntington’s disease; the company reported $16.1M of revenue in 2025 and holds $622.5M in cash and short-term…
10-Q · July 29, 2025
uniQure reported Q2 revenue of $5.262M, down 52.7% year-over-year from $11.126M but up sequentially from $1.567M in Q1. Gross margin strengthened to 87.5% while operating loss remained large at $43.865M; GAAP loss per…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.